Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2024-12-16 Regulatory Filings
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from Gencurix regarding the setting of a record date for the purpose of holding an upcoming Annual General Meeting (AGM). It specifies the record date (2024-12-31) and the reason (holding the 14th AGM). Since it is a brief regulatory notice regarding meeting preparations rather than the AGM presentation materials themselves, it falls under the general regulatory filing category.
2024-12-16 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price of convertible bonds (전환가액의 조정) for the company Gencurix. It details the specific changes to the conversion price and the number of convertible shares due to a capital event (issuance of new shares below market price). This type of filing is a standard corporate disclosure related to capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2024-12-02 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a third-party paid-in capital increase). It details the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance or capital changes.
2024-12-02 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 98% confidence The document is a regulatory filing from Gencurix regarding the 'Acquisition of Shares and Securities of Another Corporation' (타법인주식및출자증권취득결정). It details the acquisition of shares in NanoBioLife, including the number of shares, acquisition amount, purpose (financial structure improvement), and board resolution details. This type of corporate disclosure regarding investment in other entities is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like M&A (which usually implies a merger or takeover of a business entity rather than a capital injection/debt-to-equity swap in a subsidiary) or Share Issue (which is for the company's own capital changes).
2024-11-22 Korean
유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Gencurix regarding a capital increase (paid-in capital increase) of its subsidiary, Nanobiolife. It details the number of new shares, the purpose of the funds (debt repayment), the method (third-party allocation), and the board resolution date. This falls under the category of share issuance and capital changes.
2024-11-22 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Gencurix, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). This document outlines the issuance of new shares, the purpose of the capital raise (operating funds), the method (third-party allocation), and the pricing details. In the context of financial filings, an announcement regarding the issuance of new shares or capital changes is classified as a Share Issue/Capital Change filing.
2024-11-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.